Technical Analysis for IKNA - Ikena Oncology, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 1.35 | -1.46% | -0.02 |
IKNA closed down 2.84 percent on Wednesday, May 8, 2024, on 41 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: May 13
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | -1.46% | |
| Bollinger Band Squeeze | Range Contraction | -1.46% | |
| BB Squeeze + Upper Band Touch | Range Contraction | -1.46% | |
| Inside Day | Range Contraction | -1.46% | |
| Upper Bollinger Band Touch | Strength | -1.46% | |
| Crossed Above 50 DMA | Bullish | -4.26% | |
| Pocket Pivot | Bullish Swing Setup | -4.26% | |
| Bollinger Band Squeeze | Range Contraction | -4.26% | |
| BB Squeeze + Upper Band Touch | Range Contraction | -4.26% | |
| Above Upper BB | Strength | -4.26% |
| Alert | Time |
|---|---|
| Possible NR7 | 42 minutes ago |
| Gap Down Partially Closed | about 4 hours ago |
| Gap Down Closed | about 4 hours ago |
| 10 DMA Support | about 4 hours ago |
| Gapped Down (Partial) | about 5 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.43 |
| 52 Week Low | 1.02 |
| Average Volume | 300,702 |
| 200-Day Moving Average | 2.62 |
| 50-Day Moving Average | 1.39 |
| 20-Day Moving Average | 1.32 |
| 10-Day Moving Average | 1.33 |
| Average True Range | 0.09 |
| RSI (14) | 53.05 |
| ADX | 12.09 |
| +DI | 18.36 |
| -DI | 12.16 |
| Chandelier Exit (Long, 3 ATRs) | 1.16 |
| Chandelier Exit (Short, 3 ATRs) | 1.49 |
| Upper Bollinger Bands | 1.40 |
| Lower Bollinger Band | 1.24 |
| Percent B (%b) | 0.84 |
| BandWidth | 12.05 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.02 |
| MACD Histogram | 0.0138 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.51 | ||||
| Resistance 3 (R3) | 1.51 | 1.46 | 1.48 | ||
| Resistance 2 (R2) | 1.46 | 1.43 | 1.46 | 1.47 | |
| Resistance 1 (R1) | 1.42 | 1.41 | 1.40 | 1.42 | 1.47 |
| Pivot Point | 1.37 | 1.37 | 1.36 | 1.37 | 1.37 |
| Support 1 (S1) | 1.33 | 1.34 | 1.31 | 1.33 | 1.27 |
| Support 2 (S2) | 1.28 | 1.32 | 1.28 | 1.27 | |
| Support 3 (S3) | 1.24 | 1.28 | 1.26 | ||
| Support 4 (S4) | 1.24 |
